Clinical Trial Update: A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone [Phase 2]

View source ↗

Summary

Phase 2 trial in non-small cell lung cancer evaluating whether adding SU011248 (sunitinib) to erlotinib improves outcomes over erlotinib alone; the study has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sutent (sunitinib)
• Tarceva (erlotinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2011-06-10